Bronnen:
- Tabernero J, Hoff PM, Shen L et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. The Lancet Oncology. September 11, 2018DOI:https://doi.org/10.1016/S1470-2045(18)30481-9